Health Catalyst 10-K/A Reveals Significant Underperformance, Executive Departures, and Board Turnover

summarizeSummary

This amended annual report details Health Catalyst's significant underperformance against key growth metrics in 2025, leading to low executive incentive payouts and substantial board and executive changes, reinforcing a negative outlook.

check_boxKey Events · Corporate Governance and Compliance · HCAT

• Executive Compensation Reflects Poor Performance

  Named executive officers received only about 15% of their target annual performance-based incentive compensation for fiscal 2025, primarily due to failure to meet growth and client satisfaction targets. Long-term performance-based restricted stock units (PRSUs) for fiscal 2025 also saw 0% vesting for Total Shareholder Return (TSR) and Revenue Growth Rate components.

• Underperformance in Key Growth Metrics

  The company fell below minimum thresholds for net new Platform Clients, new Platform Client Annual Recurring Revenue (ARR) + Non-Recurring Revenue (NRR), and Platform Client Dollar-based Net Retention in fiscal 2025, indicating significant struggles in core business growth.

• Significant Board Turnover

  Four directors either resigned (Duncan Gallagher, S. Dawn Smith, John A. Kane) or will not be renominated (Matthew Kolb) in early 2026. This follows the appointment of Steven Nelson to the board, effective May 1, 2026, which was previously disclosed.

• Chief People Officer Departure

  Linda Llewelyn will cease to serve as Chief People Officer effective June 1, 2026. This follows the recent 8-K filing on April 27, 2026, which announced a 9% workforce reduction and the elimination of the Chief People Officer role.

auto_awesomeAnalysis · HCAT · Technology

This amended annual report provides critical details that underscore the operational challenges Health Catalyst faced in 2025, which were only broadly hinted at in the original 10-K and recent 8-K filings. The significant underperformance in core growth metrics, such as client acquisition and retention, directly impacted executive incentive compensation, with payouts far below target. This indicates a struggle to execute on strategic objectives. The high turnover on the board, with four directors departing, and the specific departure of the Chief People Officer following a workforce reduction, signal ongoing instability and strategic shifts at the leadership level. Investors should view these detailed disclosures as confirmation of the company's struggles to achieve growth and maintain stable governance, adding to the negative sentiment from recent restructuring news. The reliance on a related party for a notable portion of revenue also presents a potential risk.